Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems

Ciekot, Jarosław; Goszczyński, Tomasz Marek; Boratyński, Janusz

doi:10.1515/acph-2016-0001

Abstract

Pemetrexed (PMX) is an antifolate drug utilized in the treatment of non-small cell lung cancer. For studies of potential macromolecular carriers for PMX, fast and precise methods were developed to determine the bound and free drug contained in investigated conjugate preparations. The analysis of the total amount of PMX in conjugates was based on absorption spectrophotometry. The linearity was found in the range of 4.697–46.97 μmol L⁻¹ PMX. The limit of quantitation was 1.070 μmol L⁻¹. The method for the analysis of unbound PMX was based on size-exclusion chromatography and detection at 225 nm. This method shows linear range of 2.230–223.0 μmol L⁻¹. LOQ was 0.539 μmol L⁻¹. The proposed methods can be used both for the characterization of the polysaccharide based conjugates of PMX and for the determination of conjugate drug release profiles.

References

1. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer6 (2006) 688–701; DOI: 10.1038/Nrc1958.10.1038/nrc195816900224
Search in Google Scholar
2. M. J. Vicent and R. Duncan, Polymer conjugates: nanosized medicines for treating cancer, Trends Biotechnol. 24 (2006) 39–47; DOI: 10.1016/j.tibtech.2005.11.006.10.1016/j.tibtech.2005.11.00616307811
Search in Google Scholar
3. R. Haag and F. Kratz, Polymer the rapeutics: concepts and applications, Angew Chem. Int. Ed. Engl. 45 (2006) 1198–1215; DOI: 10.1002/anie.200502113.10.1002/anie.20050211316444775
Search in Google Scholar
4. A. A. Adjei, Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent, Clin. Cancer Res.10 (2004) 4276–4280; DOI: 10.1158/1078-0432.CCR-040010.10.1158/1078-0432.CCR-04001015217974
Search in Google Scholar
5. R. B. Zhao, N. Diop-Bove, M. Visentin and I. D. Goldman, Mechanisms of membrane transport of folates into cells and across epithelia, Ann. Rev. Nutr. 31 (2011) 177–201; DOI: 10.1146/annurev-nutr-072610-145133.10.1146/annurev-nutr-072610-145133388523421568705
Search in Google Scholar
6. J. E. Nutt, A. R. Razak, K. O’Too le, F. Black, A. E. Quinn, A. H. Calvert, E. R. Plummer and J. Lunec, The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy, Br. J. Cancer102 (2010) 553–560; DOI: 10.1038/sj.bjc.6605501.10.1038/sj.bjc.6605501282293820051956
Search in Google Scholar
7. W. H. Schuette, A. Groschel, M. S ebastian, S. Andreas, T. Muller, F. Schneller, S. Guetz, C. Eschbach, S. Bohnet, M. I. Leschinger and M. Reck, A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer, Clin. Lung Cancer14 (2013) 215–223; DOI: 10.1016/j.cllc.2012.10.001.10.1016/j.cllc.2012.10.00123332288
Search in Google Scholar
8. O. Caffo, L. Fratino, R. Barbieri, A. Perin, T. Martini, T. Sava, R. Segati, E. Vaccher, F. Bernardo Bassan, A. Veccia, G. Pappagallo nad E. Galligioni, Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study, Urol Oncol. 31 (2013) 180–186; DOI: 10.1016/j.urolonc.2010.11.012.10.1016/j.urolonc.2010.11.01221803618
Search in Google Scholar
9. A. A. Adjei, Pharmacology and mechanism of action of pemetrexed, Clin. Lung Cancer5 (2004) 51–55; DOI: 10.3816/CLC.2004.s.003.10.3816/CLC.2004.s.003
Search in Google Scholar
10. R. Budzynska, D. Nevozhay, U. Kanska, M. Jagiello, A. Opolski, J. Wietrzyk and J. Boratynski, Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo, Oncol. Res. 16 (2007) 415–421.10.3727/00000000778398083718074676
Search in Google Scholar
11. D. Nevozhay, R. Budzynska, U. Kanska, M. Jagiello, M. S. Omar, J. Boratynski and A. Opolski, Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier, Anticancer Res. 26 (2006) 1135–1143.
Search in Google Scholar
12. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment, Bioorg. Med. Chem. 17 (2009) 4647–4656; DOI: 10.1016/j.bmc.2009.04.063.10.1016/j.bmc.2009.04.06319457673
Search in Google Scholar
13. T. M. Goszczynski, B. Filip-Psurska, K. Kempinska, J. Wietrzyk and J. Boratynski, Hydroxyethyl starch as an effective methotrexate carrier in anticancer therapy, Pharmacol. Res. Perspect. 2 (2014) 1–8; DOI: 10.1002/prp2.47.10.1002/prp2.47418641525505592
Search in Google Scholar
14. M. Westphal, M. F. James, S. Kozek-Langenecker, R. Stocker, B. Guidet and H. Van Aken, Hydroxyethyl starches: different products-different effects, Anesthesiology111 (2009) 187–202; DOI: 10.1097/ALN.0b013e3181a7ec82.10.1097/ALN.0b013e3181a7ec8219512862
Search in Google Scholar
15. T. Masuko, A. Minami, N. Iwasaki, T. Majima, S. Nishimura and Y. C. Lee, Carbohydrate analysis by a phenol-sulfuric acid method in microplate format, Anal. Biochem. 339 (2005) 69–72; DOI: 10.1016/j.ab.2004.12.001.10.1016/j.ab.2004.12.00115766712
Search in Google Scholar

Methods for preliminary determination of pemetrexed in macromolecular drug-carrier systems

Abstract

Paradigm

My account